Bristol-Myers Squibb Company / Halozyme Therapeutics, Inc.
2017 · Licensing/Option · $1.9B · Complete
Announcement Sentiment
100
Strongly positive
BMS and Halozyme entered a global collaboration and license agreement for the ENHANZE subcutaneous drug delivery platform applied to up to 11 BMS immuno-oncology targets including PD-1. Halozyme received $105M upfront plus up to $160M in milestones per nominated target (~$1.76B aggregate if all 11 advance) plus additional combination-product milestones plus tiered royalties.